newsfilter
← Latest News
PR Newswire·

Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

STOCKHOLM, Sept. 13, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Abstract entitled "Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA)